{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:39:44Z","timestamp":1740980384343,"version":"3.38.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,9]],"date-time":"2011-02-09T00:00:00Z","timestamp":1297209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s11154-011-9159-3","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T07:27:07Z","timestamp":1297150027000},"page":"15-20","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of primary aldosteronism: Where are we now?"],"prefix":"10.1007","volume":"12","author":[{"given":"Asterios","family":"Karagiannis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,9]]},"reference":[{"key":"9159_CR1","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","volume":"93","author":"JW Funder","year":"2008","unstructured":"Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266\u201381.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2174\/157016110792006996","volume":"8","author":"P Anagnostis","year":"2010","unstructured":"Anagnostis P, Karagiannis A, Tziomalos K, Athyros VG, Kita M, Mikhailidis DP. Endocrine hypertension: diagnosis and management of a complex clinical entity. Curr Vasc Pharmacol. 2010;8:646\u201360.","journal-title":"Curr Vasc Pharmacol."},{"key":"9159_CR3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1677\/ERC-07-0142","volume":"14","author":"A Karagiannis","year":"2007","unstructured":"Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer. 2007;14:935\u201356.","journal-title":"Endocr Relat Cancer."},{"key":"9159_CR4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0003319709334262","volume":"60","author":"A Karagiannis","year":"2009","unstructured":"Karagiannis A, Tziomalos K, Anagnostis P, Gossios T, Athyros VG. Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization? Angiology. 2009;60:397\u2013402.","journal-title":"Angiology."},{"key":"9159_CR5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","volume":"20","author":"RD Gordon","year":"1993","unstructured":"Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol. 1993;20:296\u20138.","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"9159_CR6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","volume":"19","author":"PO Lim","year":"2001","unstructured":"Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens. 2001;19:353\u201361.","journal-title":"J Hypertens."},{"key":"9159_CR7","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1210\/jc.85.5.1863","volume":"85","author":"CE Fardella","year":"2000","unstructured":"Fardella CE, Mosso L, G\u00f3mez-S\u00e1nchez C, Cort\u00e9s P, Soto J, G\u00f3mez L, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR8","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1210\/jc.85.8.2854","volume":"85","author":"KC Loh","year":"2000","unstructured":"Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000;85:2854\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2174\/157016109787455716","volume":"7","author":"G Giacchetti","year":"2009","unstructured":"Giacchetti G, Turchi F, Boscaro M, Ronconi V. Management of primary aldosteronism: its complications and their outcomes after treatment. Curr Vasc Pharmacol. 2009;7:244\u201349.","journal-title":"Curr Vasc Pharmacol."},{"key":"9159_CR10","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","volume":"117","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510\u201326.","journal-title":"Circulation."},{"key":"9159_CR11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","volume":"12","author":"R Rocha","year":"2001","unstructured":"Rocha R, Stier Jr CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308\u201314.","journal-title":"Trends Endocrinol Metab."},{"key":"9159_CR12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/clc.20270","volume":"31","author":"C Tsioufis","year":"2008","unstructured":"Tsioufis C, Tsiachris D, Dimitriadis K, Stougiannos P, Missovoulos P, Kakkavas A, et al. Myocardial and aortic stiffening in the early course of primary aldosteronism. Clin Cardiol. 2008;31:431\u20136.","journal-title":"Clin Cardiol."},{"key":"9159_CR13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","volume":"26","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res. 1992;26:671\u20137.","journal-title":"Cardiovasc Res."},{"key":"9159_CR14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","volume":"85","author":"FJ Ramires","year":"2000","unstructured":"Ramires FJ, Mansur A, Coelho O, Maranh\u00e3o M, Gruppi CJ, Mady C, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85:1207\u201311.","journal-title":"Am J Cardiol."},{"key":"9159_CR15","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/HJH.0b013e3281268532","volume":"25","author":"R Holaj","year":"2007","unstructured":"Holaj R, Zelinka T, Wichterle D, Petr\u00e1k O, Strauch B, Widimsk\u00fd Jr J. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens. 2007;25:1451\u20137.","journal-title":"J Hypertens."},{"key":"9159_CR16","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/HJH.0b013e32831286fd","volume":"26","author":"G Bernini","year":"2008","unstructured":"Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens. 2008;26:2399\u2013405.","journal-title":"J Hypertens."},{"key":"9159_CR17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1507\/endocrj.K09E-014","volume":"56","author":"K Tsuchiya","year":"2009","unstructured":"Tsuchiya K, Yoshimoto T, Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure. Endocr J. 2009;56:553\u20139.","journal-title":"Endocr J."},{"key":"9159_CR18","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1161\/HYPERTENSIONAHA.108.128512","volume":"53","author":"S Staermose","year":"2009","unstructured":"Staermose S, Marwick TH, Gordon RD, Cowley D, Dowling A, Stowasser M. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1. Hypertension. 2009;53:e31\u20132.","journal-title":"Hypertension."},{"key":"9159_CR19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232\u20138.","journal-title":"Hypertension."},{"key":"9159_CR20","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1210\/jc.2008-2245","volume":"94","author":"LA Sechi","year":"2009","unstructured":"Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009;94:1191\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","volume":"25","author":"G Giacchetti","year":"2007","unstructured":"Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007;25:177\u201386.","journal-title":"J Hypertens."},{"key":"9159_CR23","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol."},{"key":"9159_CR24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80\u20135.","journal-title":"Arch Intern Med."},{"key":"9159_CR25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jc.2008-2116","volume":"94","author":"E Born-Frontsberg","year":"2009","unstructured":"Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn\u2019s Registry. J Clin Endocrinol Metab. 2009;94:1125\u201330.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR26","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3\u201317.","journal-title":"J Lab Clin Med."},{"key":"9159_CR27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0002-9343(67)90065-4","volume":"42","author":"WW Davis","year":"1967","unstructured":"Davis WW, Newsome Jr HH, Wright Jr LD, Hammond WG, Easton J, Bartter FC. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity. Am J Med. 1967;42:642\u20137.","journal-title":"Am J Med."},{"key":"9159_CR28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"WF Young","year":"2007","unstructured":"Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66:607\u201318.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"9159_CR29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262\u20135.","journal-title":"Nature."},{"issue":"1 Pt 2","key":"9159_CR30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/01.HYP.31.1.445","volume":"31","author":"WR Litchfield","year":"1998","unstructured":"Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension. 1998;31(1 Pt 2):445\u201350.","journal-title":"Hypertension."},{"key":"9159_CR31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.hjh.0000174299.66369.26","volume":"23","author":"A So","year":"2005","unstructured":"So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens. 2005;23:1477\u201384.","journal-title":"J Hypertens."},{"key":"9159_CR32","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","volume":"93","author":"DS Geller","year":"2008","unstructured":"Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93:3117\u201323.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/000313480206800307","volume":"68","author":"H Rossi","year":"2002","unstructured":"Rossi H, Kim A, Prinz RA. Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg. 2002;68:253\u20136.","journal-title":"Am Surg."},{"key":"9159_CR34","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/bjs.4738","volume":"91","author":"A Assalia","year":"2004","unstructured":"Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg. 2004;91:1259\u201374.","journal-title":"Br J Surg."},{"key":"9159_CR35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s002689900407","volume":"22","author":"J Sir\u00e9n","year":"1998","unstructured":"Sir\u00e9n J, V\u00e4lim\u00e4ki M, Huikuri K, Sivula A, Voutilainen P, Haapiainen R. Adrenalectomy for primary aldosteronism: long-term follow-up study in 29 patients. World J Surg. 1998;22:418\u201321.","journal-title":"World J Surg."},{"key":"9159_CR36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archsurg.134.6.628","volume":"134","author":"WT Shen","year":"1999","unstructured":"Shen WT, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, et al. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg. 1999;134:628\u201331.","journal-title":"Arch Surg."},{"key":"9159_CR37","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/BF02067355","volume":"16","author":"G Favia","year":"1992","unstructured":"Favia G, Lumachi F, Scarpa V, D\u2019Amico DF. Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients. World J Surg. 1992;16:680\u20133.","journal-title":"World J Surg."},{"key":"9159_CR38","first-page":"987","volume":"112","author":"T Obara","year":"1992","unstructured":"Obara T, Ito Y, Okamoto T, Kanaji Y, Yamashita T, Aiba M, et al. Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery. 1992;112:987\u201393.","journal-title":"Surgery."},{"key":"9159_CR39","first-page":"1189","volume":"114","author":"D Simon","year":"1993","unstructured":"Simon D, Goretzki PE, Lollert A, R\u00f6her HD. Persistent hypertension after successful adrenal operation. Surgery. 1993;114:1189\u201395.","journal-title":"Surgery."},{"key":"9159_CR40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.7326\/0003-4819-121-11-199412010-00010","volume":"121","author":"JD Blumenfeld","year":"1994","unstructured":"Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan Jr ED, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994;121:877\u201385.","journal-title":"Ann Intern Med."},{"key":"9159_CR41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00000658-199404000-00004","volume":"219","author":"RJ Weigel","year":"1994","unstructured":"Weigel RJ, Wells SA, Gunnells JC, Leight GS. Surgical treatment of primary hyperaldosteronism. Ann Surg. 1994;219:347\u201352.","journal-title":"Ann Surg."},{"key":"9159_CR42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/archsurg.1996.01430180072015","volume":"131","author":"O Celen","year":"1996","unstructured":"Celen O, O\u2019Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg. 1996;131:646\u201350.","journal-title":"Arch Surg."},{"key":"9159_CR43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00000658-199608000-00003","volume":"224","author":"CY Lo","year":"1996","unstructured":"Lo CY, Tam PC, Kung AW, Lam KS, Wong J. Primary aldosteronism. Results of surgical treatment. Ann Surg. 1996;224:125\u201330.","journal-title":"Ann Surg."},{"key":"9159_CR44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1067\/msy.1998.93108","volume":"124","author":"CA Proye","year":"1998","unstructured":"Proye CA, Mulliez EA, Carnaille BM, Lecomte-Houcke M, Decoulx M, W\u00e9meau JL, et al. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery. 1998;124:1128\u201333.","journal-title":"Surgery."},{"key":"9159_CR45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/110241599750007027","volume":"165","author":"P Sapienza","year":"1999","unstructured":"Sapienza P, Cavallaro A. Persistent hypertension after removal of adrenal tumours. Eur J Surg. 1999;165:187\u201392.","journal-title":"Eur J Surg."},{"key":"9159_CR46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1067\/msy.2001.116920","volume":"130","author":"LM Brunt","year":"2001","unstructured":"Brunt LM, Moley JF, Doherty GM, Lairmore TC, DeBenedetti MK, Quasebarth MA. Outcomes analysis in patients undergoing laparoscopic adrenalectomy for hormonally active adrenal tumors. Surgery. 2001;130:629\u201334.","journal-title":"Surgery."},{"key":"9159_CR47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","volume":"135","author":"AM Sawka","year":"2001","unstructured":"Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135:258\u201361.","journal-title":"Ann Intern Med."},{"key":"9159_CR48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1291\/hypres.25.11","volume":"25","author":"Y Fukudome","year":"2002","unstructured":"Fukudome Y, Fujii K, Arima H, Ohya Y, Tsuchihashi T, Abe I, et al. Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy. Hypertens Res. 2002;25:11\u20138.","journal-title":"Hypertens Res."},{"key":"9159_CR49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0748-7983(03)00051-9","volume":"29","author":"DA Harris","year":"2003","unstructured":"Harris DA, Au-Yong I, Basnyat PS, Sadler GP, Wheeler MH. Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur J Surg Oncol. 2003;29:467\u201374.","journal-title":"Eur J Surg Oncol."},{"key":"9159_CR50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(05)64028-1","volume":"169","author":"P Meria","year":"2003","unstructured":"Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J Urol. 2003;169:32\u20135.","journal-title":"J Urol."},{"key":"9159_CR51","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00004872-200311000-00025","volume":"21","author":"M Stowasser","year":"2003","unstructured":"Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after \u2018non-selective\u2019 screening of hypertensive patients. J Hypertens. 2003;21:2149\u201357.","journal-title":"J Hypertens."},{"key":"9159_CR52","first-page":"320","volume":"8","author":"BK Goh","year":"2004","unstructured":"Goh BK, Tan YH, Yip SK, Eng PH, Cheng CW. Outcome of patients undergoing laparoscopic adrenalectomy for primary hyperaldosteronism. JSLS. 2004;8:320\u20135.","journal-title":"JSLS."},{"key":"9159_CR53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00268-004-7496-z","volume":"29","author":"A Meyer","year":"2005","unstructured":"Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg. 2005;29:155\u20139.","journal-title":"World J Surg."},{"key":"9159_CR54","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/000313480707300218","volume":"73","author":"I Gockel","year":"2007","unstructured":"Gockel I, Heintz A, Polta M, Junginger T. Long-term results of endoscopic adrenalectomy for Conn\u2019s syndrome. Am Surg. 2007;73:174\u201380.","journal-title":"Am Surg."},{"key":"9159_CR55","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1445-2197.2007.04225.x","volume":"77","author":"TC Pang","year":"2007","unstructured":"Pang TC, Bambach C, Monaghan JC, Sidhu SB, Bune A, Delbridge LW, et al. Outcomes of laparoscopic adrenalectomy for hyperaldosteronism. ANZ J Surg. 2007;77:768\u201373.","journal-title":"ANZ J Surg."},{"key":"9159_CR56","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/000313480507101015","volume":"71","author":"F Lumachi","year":"2005","unstructured":"Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg. 2005;71:864\u20139.","journal-title":"Am Surg."},{"key":"9159_CR57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/qjmed\/hci143","volume":"98","author":"A Karagiannis","year":"2005","unstructured":"Karagiannis A, Tziomalos K, Dona K, Pyrpasopoulou A, Kartali N, Athyros V, et al. Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient. QJM. 2005;98:913\u20135.","journal-title":"QJM."},{"key":"9159_CR58","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820\u20135.","journal-title":"Am J Cardiol."},{"key":"9159_CR59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217:27\u201331.","journal-title":"Mol Cell Endocrinol."},{"key":"9159_CR60","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","volume":"240","author":"M Gasparo de","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjou\u00e9 HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650\u20136.","journal-title":"J Pharmacol Exp Ther."},{"key":"9159_CR61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ndt\/gfl500","volume":"22","author":"A Karagiannis","year":"2007","unstructured":"Karagiannis A, Tziomalos K, Kakafika A, Florentin M, Athyros VG. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant. 2007;22:293.","journal-title":"Nephrol Dial Transplant."},{"key":"9159_CR62","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","volume":"9","author":"A Karagiannis","year":"2008","unstructured":"Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9:509\u201315.","journal-title":"Expert Opin Pharmacother."},{"key":"9159_CR63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/clpt.1982.9","volume":"31","author":"GT Griffing","year":"1982","unstructured":"Griffing GT, Cole AG, Aurecchia SA, Sindler BH, Komanicky P, Melby JC. Amiloride in primary hyperaldosteronism. Clin Pharmacol Ther. 1982;31:56\u201361.","journal-title":"Clin Pharmacol Ther."},{"key":"9159_CR64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0039-128X(94)00018-8","volume":"60","author":"F Mantero","year":"1995","unstructured":"Mantero F, Opocher G, Rocco S, Carpen\u00e8 G, Armanini D. Long-term treatment of mineralocorticoid excess syndromes. Steroids. 1995;60:81\u20136.","journal-title":"Steroids."},{"key":"9159_CR65","first-page":"579","volume":"4","author":"F Veglio","year":"1990","unstructured":"Veglio F, Pinna G, Bisbocci D, Rabbia F, Piras D, Chiandussi L. Efficacy of nicardipine slow release (SR) on hypertension, potassium balance and plasma aldosterone in idiopathic aldosteronism. J Hum Hypertens. 1990;4:579\u201382.","journal-title":"J Hum Hypertens."},{"key":"9159_CR66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/pgmj.75.882.235","volume":"75","author":"MJ Brown","year":"1999","unstructured":"Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn\u2019s syndrome. Postgrad Med J. 1999;75:235\u20136.","journal-title":"Postgrad Med J."},{"issue":"Suppl 7","key":"9159_CR67","doi-asserted-by":"crossref","first-page":"289s","DOI":"10.1042\/cs061289s","volume":"61","author":"F Mantero","year":"1981","unstructured":"Mantero F, Fallo F, Opocher G, Armanini D, Boscaro M, Scaroni C. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin Sci (Lond). 1981;61 Suppl 7:289s\u201393s.","journal-title":"Clin Sci (Lond)."},{"key":"9159_CR68","first-page":"265","volume":"1","author":"GT Griffing","year":"1985","unstructured":"Griffing GT, Melby JC. The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate, in idiopathic hyperaldosteronism. J Clin Hypertns. 1985;1:265\u201376.","journal-title":"J Clin Hypertns."},{"key":"9159_CR69","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1210\/jcem-47-5-938","volume":"47","author":"M Wisgerhof","year":"1978","unstructured":"Wisgerhof M, Carpenter PC, Brown RD. Increased adrenal sensitivity to angiotensin II in idiopathic hyperaldosteronism. J Clin Endocrinol Metab. 1978;47:938\u201343.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR70","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00004872-200106000-00022","volume":"19","author":"GS Stokes","year":"2001","unstructured":"Stokes GS, Monaghan JC, Ryan M, Woodward M. Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism. J Hypertens. 2001;19:1161\u20135.","journal-title":"J Hypertens."},{"key":"9159_CR71","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.hjh.0000226205.65442.f2","volume":"24","author":"J M\u00e9nard","year":"2006","unstructured":"M\u00e9nard J, Gonzalez MF, Guyene TT, Bissery A. Investigation of aldosterone-synthase inhibition in rats. J Hypertens. 2006;24:1147\u201355.","journal-title":"J Hypertens."},{"issue":"1 Pt 1","key":"9159_CR72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/01.HYP.29.1.45","volume":"29","author":"Y Takeda","year":"1997","unstructured":"Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension. 1997;29(1 Pt 1):45\u20138.","journal-title":"Hypertension."},{"key":"9159_CR73","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","volume":"273","author":"JS Silvestre","year":"1998","unstructured":"Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem. 1998;273:4883\u201391.","journal-title":"J Biol Chem."},{"key":"9159_CR74","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1210\/en.2004-0081","volume":"145","author":"N Ahmad","year":"2004","unstructured":"Ahmad N, Romero DG, Gomez-Sanchez EP, Gomez-Sanchez CE. Do human vascular endothelial cells produce aldosterone? Endocrinolgy. 2004;145:3626\u20139.","journal-title":"Endocrinolgy."},{"key":"9159_CR75","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","volume":"111","author":"A Fiebeler","year":"2005","unstructured":"Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005;111:3087\u201394.","journal-title":"Circulation."},{"key":"9159_CR76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.32.2.198","volume":"32","author":"E Brand","year":"1998","unstructured":"Brand E, Chatelain N, Mulatero P, F\u00e9ry I, Curnow K, Jeunemaitre X, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension. 1998;32:198\u2013204.","journal-title":"Hypertension."},{"key":"9159_CR77","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1210\/jc.83.3.1033","volume":"83","author":"SE Taymans","year":"1998","unstructured":"Taymans SE, Pack S, Pak E, Torpy DJ, Zhuang Z, Stratakis CA. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab. 1998;83:1033\u20136.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR78","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200018040-00001","volume":"18","author":"MK Raizada","year":"2000","unstructured":"Raizada MK, Francis SC, Wang H, Gelband CH, Reaves PY, Katovich MJ. Targeting of the renin-angiotensin system by antisense gene therapy: a possible strategy for the long-term control of hypertension. J Hypertens. 2000;18:353\u201362.","journal-title":"J Hypertens."},{"key":"9159_CR79","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11154-007-9055-z","volume":"8","author":"WF Young Jr","year":"2007","unstructured":"Young Jr WF. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord. 2007;8:309\u201320.","journal-title":"Rev Endocr Metab Disord."},{"key":"9159_CR80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0960-0760(01)00097-8","volume":"78","author":"M Stowasser","year":"2001","unstructured":"Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem Mol Biol. 2001;78:215\u201329.","journal-title":"J Steroid Biochem Mol Biol."},{"key":"9159_CR81","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1210\/jc.2009-1399","volume":"94","author":"M Stowasser","year":"2009","unstructured":"Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2009;94:3623\u201330.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR82","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00000658-196308000-00006","volume":"158","author":"JW Gilbert","year":"1963","unstructured":"Gilbert JW, Bell NH, Bartter FC. Primary aldosteronism: diagnosis and surgical treatment. Ann Surg. 1963;158:195\u2013204.","journal-title":"Ann Surg."},{"key":"9159_CR83","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0002-9343(70)90065-3","volume":"48","author":"JM George","year":"1970","unstructured":"George JM, Wright L, Bell NH, Bartter FC. The syndrome of primary aldosteronism. Am J Med. 1970;48:343\u201356.","journal-title":"Am J Med."},{"key":"9159_CR84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-90-3-386","volume":"90","author":"MH Weinberger","year":"1979","unstructured":"Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ, et al. Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med. 1979;90:386\u201395.","journal-title":"Ann Intern Med."},{"key":"9159_CR85","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1210\/jc.2008-2803","volume":"94","author":"N Sukor","year":"2009","unstructured":"Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab. 2009;94:2437\u201345.","journal-title":"J Clin Endocrinol Metab."},{"key":"9159_CR86","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1677\/ERC-08-0094","volume":"15","author":"A Karagiannis","year":"2008","unstructured":"Karagiannis A, Tziomalos K, Kakafika AI, Athyros VG, Harsoulis F, Mikhailidis DP. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocr Relat Cancer. 2008;15:693\u2013700.","journal-title":"Endocr Relat Cancer."},{"key":"9159_CR87","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/bmj.2.5816.729","volume":"2","author":"JJ Brown","year":"1972","unstructured":"Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF, et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J. 1972;2:729\u201334.","journal-title":"Br Med J."},{"key":"9159_CR88","first-page":"493","volume-title":"Hypertension: mechanisms and management","author":"EG Biglieri","year":"1973","unstructured":"Biglieri EG, Schambelan M. Management of primary aldosteronism. In: Onesti G, Kim KE, Moyer JH, editors. Hypertension: mechanisms and management. New York: Grune and Stratton; 1973. p. 493\u20138."},{"key":"9159_CR89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0002-8703(78)90132-1","volume":"96","author":"JB Ferriss","year":"1978","unstructured":"Ferriss JB, Beevers DG, Boddy K, Brown JJ, Davies DL, Fraser R, et al. The treatment of low-renin (\u201cprimary\u201d) hyperaldosteronism. Am Heart J. 1978;96:97\u2013109.","journal-title":"Am Heart J."},{"key":"9159_CR90","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-131-2-199907200-00005","volume":"131","author":"RP Ghose","year":"1999","unstructured":"Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med. 1999;131:105\u20138.","journal-title":"Ann Intern Med."},{"key":"9159_CR91","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1046\/j.1365-2168.2002.02261.x","volume":"89","author":"M Sywak","year":"2002","unstructured":"Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002;89:1587\u201393.","journal-title":"Br J Surg."},{"key":"9159_CR92","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08998280.2004.11927973","volume":"17","author":"J Craft","year":"2004","unstructured":"Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Bayl Univ Med Cent). 2004;17:217\u201320.","journal-title":"Proc (Bayl Univ Med Cent)."}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-011-9159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11154-011-9159-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-011-9159-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T12:40:20Z","timestamp":1740919220000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11154-011-9159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,9]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["9159"],"URL":"https:\/\/doi.org\/10.1007\/s11154-011-9159-3","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"type":"print","value":"1389-9155"},{"type":"electronic","value":"1573-2606"}],"subject":[],"published":{"date-parts":[[2011,2,9]]}}}